Tyme Technologies logo
Tyme Technologies TYME

Quarterly report 2022-Q2
added 08-09-2022

report update icon

Tyme Technologies Balance Sheet 2011-2026 | TYME

Annual Balance Sheet Tyme Technologies

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-107 M -26.1 M -13.7 M -28.5 M -10.5 M - -4.45 M - - -16 K -8.9 K

Long Term Debt

41.3 K - - - - - - - - - -

Long Term Debt Current

34.7 K 54.7 K - - - - - - - - -

Total Non Current Liabilities

- 4.89 M 1.54 M - - - - - - - -

Total Current Liabilities

5.64 M 5.58 M 6.31 M 4.55 M 3.33 M 1.91 M 1.47 M 96.5 K 42.6 K - -

Total Liabilities

8.47 M 10.5 M 7.85 M 4.55 M 3.33 M - 1.47 M 96.5 K 42.6 K 2 K 2 K

Retained Earnings

-137 M -108 M -85.8 M -52.8 M -33.9 M - -15.9 M -140 K -86.1 K -29.5 K -2.1 K

Total Assets

110 M 29.5 M 17.5 M 31 M 10.7 M - 4.49 M - - 16 K 8.9 K

Cash and Cash Equivalents

108 M 26.7 M 14.3 M 29 M 10.5 M 6.11 M 4.45 M 9.72 K 92.6 K 16 K 8.9 K

Book Value

102 M 19 M 9.67 M 26.5 M 7.39 M - 3.02 M -96.5 K -42.6 K 14 K 6.9 K

Total Shareholders Equity

102 M 19 M 9.67 M 26.5 M 7.39 M 4.43 M 3.02 M -96.5 K -42.6 K 14 K 6.9 K

All numbers in USD currency

Quarterly Balance Sheet Tyme Technologies

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 7.81 K 19.3 K 30.4 K 41.3 K 51.8 K - - - 10.2 K 26.7 K 42 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 6.02 M 7.93 M 6.31 M 6.3 M 6.62 M 8.47 M 6.64 M 7.6 M 8.15 M 10.5 M 11.3 M 10.3 M 10.1 M 7.85 M 3.5 M 3.25 M 2.99 M 4.55 M 3.71 M 3.05 M 3.21 M 3.33 M 2.6 M 2.35 M 1.74 M 1.91 M 1.47 M 1.67 M 1.41 M 1.47 M 2.64 M 2.64 M 2.64 M 2.64 M 42.6 K 42.6 K 42.6 K 42.6 K 2 K 2 K 2 K 2 K 2 K 2 K 2 K 2 K

Retained Earnings

- - -167 M -160 M -154 M -148 M -143 M -137 M -130 M -123 M -117 M -108 M -102 M -95.1 M -89 M -85.8 M -74.6 M -66.6 M -59.6 M -52.8 M -47.5 M -42 M -36.7 M -33.9 M -30.8 M -27.8 M -24.7 M -18.7 M -15.9 M -13.8 M -11.5 M -15.9 M -4.18 M -4.17 M -4.17 M -4.17 M -86.1 K - - -36.8 K -29.5 K -26.7 K -13.6 K -29.5 K -2.1 K -2.1 K -2.1 K -2.1 K

Total Assets

- - 80.2 M 88 M 93 M 97.8 M 103 M 110 M 15.8 M 22.1 M 24 M 29.5 M 13.7 M 17.6 M 22.1 M 17.5 M 19.2 M 24 M 25.1 M 31 M 12.6 M 8.7 M 11.8 M 10.7 M 3.05 M 3.21 M 4.39 M 6.34 M 4.49 M 2.02 M 3.77 M 4.49 M 167 K 167 K 167 K 167 K - 68 68 8.7 K 16 K 16 K 16 K 16 K 8.9 K 8.9 K 8.9 K 8.9 K

Cash and Cash Equivalents

- - 6.42 M 13.7 M 20.8 M 29.2 M 36.5 M 108 M 13.5 M 19.4 M 21.3 M 26.7 M 11.5 M 15.3 M 19.5 M 14.3 M 16.7 M 16.7 M 21.1 M 29 M 10.8 M 7.51 M 10.5 M 10.5 M 2.99 M 3.08 M 4.21 M 6.11 M 4.45 M 4.45 M 4.45 M 4.45 M 9.72 K 9.72 K 9.72 K 9.72 K 92.6 K 68 68 8.73 K 16 K 16 K 16 K 16 K 8.9 K 8.9 K 8.9 K 8.9 K

Book Value

- - 74.1 M 80.1 M 86.7 M 91.5 M 96.5 M 102 M 9.17 M 14.5 M 15.8 M 19 M 2.4 M 7.31 M 12 M 9.67 M 15.7 M 20.8 M 22.1 M 26.5 M 8.89 M 5.65 M 8.58 M 7.39 M 451 K 859 K 2.65 M 4.43 M 3.02 M 352 K 2.36 M 3.02 M -2.47 M -2.47 M -2.47 M -2.47 M -42.6 K -42.5 K -42.5 K -33.9 K 14 K 14 K 14 K 14 K 6.9 K 6.9 K 6.9 K 6.9 K

Total Shareholders Equity

- - 74.1 M 80.1 M 86.7 M 91.5 M 96.5 M 102 M 9.17 M 9.17 M 14.5 M 15.8 M 2.4 M 2.4 M 7.31 M 12 M 15.7 M 15.7 M 20.8 M 26.5 M 8.89 M 5.65 M 8.58 M 7.39 M 451 K 859 K 2.65 M 4.43 M 3.02 M 352 K 2.36 M 2.71 M -2.12 M -82.6 K -69.1 K -2.12 M -42.6 K -42.6 K -42.6 K -42.6 K 14 K 14 K 14 K 14 K 6.9 K 6.9 K 6.9 K 6.9 K

All numbers in USD currency

Balance Sheet is a fundamental financial report of Tyme Technologies, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.44 -4.32 % $ 1.03 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -1.15 % $ 4.31 M chinaChina
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
ADMA Biologics ADMA Biologics
ADMA
$ 15.36 -2.17 % $ 3.66 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.28 0.65 % $ 2.56 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.51 1.35 % $ 385 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.05 -1.44 % $ 206 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 74.36 -1.64 % $ 1.44 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 162.43 0.6 % $ 8.08 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 8.49 -0.18 % $ 1.75 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 65.66 -0.78 % $ 12.6 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.69 -0.74 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 61.3 1.21 % $ 11.8 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 7.79 -5.75 % $ 1.28 B britainBritain
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Codexis Codexis
CDXS
$ 1.23 -2.38 % $ 90.3 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.18 -0.16 % $ 3.71 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA